Plus Therapeutics (PSTV)
NASDAQ:PSTV
Want to see PSTV full AI Analyst Report?
Total Valuation
Plus Therapeutics has a market cap or net worth of $40.20M. The enterprise value is $13.26M.
Market Cap$40.20M
Enterprise Value$13.26M
Share Statistics
Plus Therapeutics has 6,883,106 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,883,106
Owned by Insiders15.34%
Owned by Institutions―
Financial Efficiency
Plus Therapeutics’s return on equity (ROE) is -5.60 and return on invested capital (ROIC) is -317.58%.
Return on Equity (ROE)-5.60
Return on Assets (ROA)-1.37
Return on Invested Capital (ROIC)-317.58%
Return on Capital Employed (ROCE)-3.81
Revenue Per Employee248.24K
Profits Per Employee-1.07M
Employee Count21
Asset Turnover0.32
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Plus Therapeutics is ―. Plus Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio7.65
PB Ratio9.98
Price to Fair Value9.98
Price to FCF-1.91
Price to Operating Cash Flow-2.05
PEG Ratio0.02
Income Statement
In the last 12 months, Plus Therapeutics had revenue of 5.21M and earned -22.39M in profits. Earnings per share was -7.19.
Revenue5.21M
Gross Profit4.77M
Operating Income-15.30M
Pretax Income-22.39M
Net Income-22.39M
EBITDA-14.85M
Earnings Per Share (EPS)-7.19
Cash Flow
In the last 12 months, operating cash flow was -20.84M and capital expenditures -882.00K, giving a free cash flow of -21.72M billion.
Operating Cash Flow-20.84M
Free Cash Flow-21.72M
Free Cash Flow per Share-3.16
Dividends & Yields
Plus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.46
52-Week Price Change-24.17%
50-Day Moving Average5.78
200-Day Moving Average10.79
Relative Strength Index (RSI)56.12
Average Volume (3m)404.84K
Important Dates
Plus Therapeutics upcoming earnings date is Aug 19, 2026, After Close (Confirmed).
Last Earnings DateApr 16, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
Plus Therapeutics as a current ratio of 1.23, with Debt / Equity ratio of 6.06%
Current Ratio1.23
Quick Ratio1.23
Debt to Market Cap0.02
Net Debt to EBITDA0.53
Interest Coverage Ratio-4.24
Taxes
In the past 12 months, Plus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Plus Therapeutics EV to EBITDA ratio is -2.15, with an EV/FCF ratio of -1.53.
EV to Sales6.13
EV to EBITDA-2.15
EV to Free Cash Flow-1.53
EV to Operating Cash Flow-1.54
Balance Sheet
Plus Therapeutics has $3.02M in cash and marketable securities with $725.00K in debt, giving a net cash position of $2.30M billion.
Cash & Marketable Securities$3.02M
Total Debt$725.00K
Net Cash$2.30M
Net Cash Per Share$0.33
Tangible Book Value Per Share$1.06
Margins
Gross margin is 92.80%, with operating margin of -293.46%, and net profit margin of -429.43%.
Gross Margin92.80%
Operating Margin-293.46%
Pretax Margin-429.43%
Net Profit Margin-429.43%
EBITDA Margin-284.92%
EBIT Margin-293.46%
Analyst Forecast
The average price target for Plus Therapeutics is $38.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$38.00
Price Target Upside6451.72% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-0.46%
EPS Growth Forecast96.28%